Open Calls for Proposals

EP PerMed will fund research projects in human health on innovative PM strategies for

patients with cardiovascular, metabolic or kidney diseases. Research projects may focus on a single disease or explore these conditions in combination. Proposals should address one or more of the

following aspects:

• Development and validation ofinnovative personalised therapeutic approachesfor cardiovascular, metabolic or kidney diseases through testing in relevant pre-clinical models
• Identification and validation of molecular markers/signatures or cutting-edge technologies

to monitor treatment response in patients with cardiovascular, metabolic or kidney diseases in order to tailor treatment pathways.

• Identification and validation of stratifying molecular markers/signatures or stratifying diagnostic technologiesfor early disease risk prediction and prevention of disease worsening or comorbiditiesin patients with cardiovascular, metabolic or kidney diseases, thereby delaying the progression to cardiovascular-kidney-metabolic syndrome.

Funding: up to 140K EUR for Israeli PIs

https://www.eppermed.eu/funding-projects/calls/jtc2026

* A short abstract and budget should be sent to the ministry of Health (MOH) prior to pre-proposal submission. Call us for clarifications and MOH abstract forms (tel. 2152, 1272, 1477).

An information webinar for potential applicants will take place on 16 December, 11:00–13:00 CET:

For registration: https://www.eppermed.eu/news-events/events/ep-permed-jtc2026-information-day/

The call will be implemented in two stages, a pre- and a full-proposal phase.
The call will welcome proposals focused on providing diagnostic clarity in unsolved rare genetic and non‑genetic diseases. Involving patient organizations from the very start is highly desirable.
Funding: up to 140K EUR (additional 40K EUR for Israeli coordinators)
https://erdera.org/call/joint-transnational-call-2026/
* A short abstract and budget should be sent to the ministry of Health (MOH) prior to pre-proposal submission. Call us for clarifications and MOH abstract forms (tel. 2152, 1272, 1477).
An information webinar for potential applicants will take place on 16 December, 15:00–17:00 CET:
For registration: https://erdera.org/event/information-webinar-erdera-joint-transnational-call-2026/

Research proposals to be submitted jointly by British and Israeli scientists that seek to further the understanding of ageing and its impact on human health and well-being. Welcome projects that use a holistic approach to healthy ageing, including pioneering techniques, state-of-the-art technologies and interdisciplinary approaches, showcasing the added value of international collaboration.
Funding: up to £400K for 3 years
BIRAX Healthy Ageing Sub-call for Follow-on Funding
This opportunity is open exclusively to previous project leads and co-leads of BIRAX-funded projects, enabling them to build on their successful research under the BIRAX Program (Regenerative Medicine Initiative and Healthy Ageing).
https://www.britishcouncil.org.il/en/birax/call-for-proposals

The aim of the call is to facilitate multinational, collaborative and interdisciplinary research that addresses critical translational questions. Applications for this call, should address how biological, social and environmental factors affect the trajectory of neurodegenerative disorders1 across the lifespan.

Applications must be interdisciplinary and address at least two of the three factors impacting brain health trajectories in the field of neurodegenerative disorders:

1) Biological factors, e.g. genetics, epigenetics, -omics, neuroplasticity, inflammation, infection, synaptogenesis, circuits, vascular factors, sensory impairment, co-morbidities;

2) Lifestyle and social factors, e.g. exercise/activity, nutrition, sleep, smoking, alcohol and drug abuse, work (income, employment), socio-economic background/status, race/ethnicity, sex and gender, education, safety, social interactions (family/friends), access to healthcare, stress, trauma, migration. 3) Environmental factors, e.g. pollution/contaminants, urbanicity, disasters, pandemics, war/conflicts, climate change, microbiota, nature.

Funding for the Israeli partner: about €140,000 over 3 years.

* A short abstract and budget should be sent to the ministry of Health (MOH) prior to pre-proposal submission. Call us for clarifications and MOH abstract forms (tel. 2152, 1272).

https://www.brainhealth-partnership.eu/calls/jtc2026-neurodegenerative-disorders/

*Please contact the Research Authority if planning to submit.

**Registration and obtaining reference number 17.3, LOI due 26.3

HFSP supports international collaborations in fundamental Life Sciences research with emphasis on innovative and interdisciplinary approaches to understanding complex mechanisms of living organisms. Preliminary results are not required.

Research Grants – Program: to teams of independent researchers at any stage of their careers. The research team is expected to develop new lines of research through the collaboration. Applications including independent investigators early in their careers are encouraged.

Early Career: all members must be within 5 years of obtaining an independent position and must have obtained their first doctoral degree (PhD, MD or equivalent) no longer than 10 years before the deadline for submission of the Letter of Intent. They must be in a position to initiate and direct their own independent lines of research.

Funding: Grants provide 3 years support.

Awards are dependent upon team size (for instance 2-member teams will receive 300 000 USD and 4-member teams 500 000 USD per year.

The principal applicant must be located in one of the member countries [Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Cyprus (EU part), the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, India, the Republic of Ireland, Israel, Italy, Japan, the Republic of Korea, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, New Zealand, Poland, Portugal, Romania, Singapore, Slovakia, Slovenia, Spain, Sweden, Switzerland, the United Kingdom, and the United States of America..]. Co-investigators may be in any country, with at least one in a country other than the PA. The number of team members should normally be 2 – 4.

https://www.hfsp.org/funding/hfsp-funding/research-grants

קרן דליה גרידינגר ז”ל למלחמה בסרטן: קול קורא לתמיכה בחוקרים צעירים בתחום הסרטן

הקרן תומכת בחוקרים צעירים, עד גיל  45, למחקר בתחום הסרטן. מימון: 100,000 ש”ח לשנתיים.

Dahlia Greidinger Foundation – Cancer Research

A competitive funding instrument for networking events to share knowledge on rare diseases and rare cancers.  ERDERA supports the organization of transnational networking events that promote knowledge sharing, research uptake and collaborations among clinicians, researchers, and patients/patient advocacy organizations (PAOs).

Funding: up to €30 000 per networking event

Networking Support Scheme – ERDERA

Supports junior postdoctoral researchers who are undertaking projects with high scientific merit and relevance to ALS. Individuals who received their Ph.D. or completed their postgraduate clinical training on or after February 10, 2024, are eligible to apply.

Funding: up to $150K over two years

www.als.org/sites/default/files/2025-12/FY27_Safenowitz%20RFA.pdf

General Research Grant

Supports research across the spectrum from basic research through drug development and clinical research programs in Friedreich’s Ataxia (FA).

Funding: $125K for 1-2 years

FARA is willing to consider ad-hoc proposals of cycle that are high-value projects. For more information, please contact FARA at grants@curefa.org

Keith Michael Andrus Cardiac Award proposals for this award should focus on advancing understanding and/or treatment of the cardiac involvement in FA.
$125,000 per year for 1 or 2 years

Kyle Bryant Translational Research Award Eligible applications should focus on accelerating completion of translational stage activities necessary for advancement to clinical study of a therapeutic candidate or development of novel tools that address a critical bottleneck to the discovery or development of therapies.
$200,000 per year for 1 or 2 years

Bronya J. Keats Research Collaboration Award . Proposals should focus on FA research that relies on collaboration among investigators from at least two different institutions. Special consideration will be given to proposals that involve international collaborations and bring new scientists to the FA community. The rationale for the collaboration needs to be convincing: it must clearly demonstrate that the research goals could not be achieved by just one of the participating groups and the synergy among the groups is essential for the success of the project.
$175,000 per year for 1 or 2 years

https://www.curefa.org/research/grant-program/grant-type/

To encourage innovative research in the fields of diabetes and its complications, and to promote excellence in medical education. Applicants should have demonstrated their ability in the field of diabetes research.
Funding: 50K EUR award
Applications can be submitted by early career scientists: scientists and clinicians at an early stage of their career, up to 7 years since completion of their most recent degree.
https://www.europeandiabetesfoundation.org/programmes/programme-calls/efsd-and-lilly-young-investigator-research-award-programme/
www.europeandiabetesfoundation.org/programmes/current-funding-opportunities

To identify promising and innovative young researchers who are developing their research activities in Europe.
Applications can be submitted by early career scientists: scientists and clinicians at an early stage of their career, up to 7 years since completion of their most recent degree.
Funding: 30K EUR award
The chosen candidates will be invited by EASD to present a lecture (20-minute lecture + 5-minute discussion) and will receive a commemorative diploma. Travel expenses, hotel and registration costs for the recipients will be covered.
https://www.europeandiabetesfoundation.org/programmes/programme-calls/easd-rising-star-symposium-and-efsd-rising-star-fellowship-programme/
www.europeandiabetesfoundation.org/programmes/current-funding-opportunities

Solution Pitch due: March 26
What if our most advanced biological medicines were as easy to ship and store as aspirin?
The BioStabilization Systems (BoSS) program aims to make the seemingly impossible problem of room temperature biologics possible by pioneering new technologies to produce, store, and ship cells at room temperature, without any need for refrigeration. The program will eliminate deep freeze requirements, paving the way for a new era of efficient and resilient manufacturing and distribution of biologic drugs.
https://arpa-h.gov/explore-funding/programs/boss

Funds research projects to develop alternative methods that replace or reduce the use of animals in research. Projects can be focused on research, testing, or education alternatives.

Funding: $50K for 1 year

https://www.ardf-online.org/ardf-grants.html

Applicants may submit a pre-proposal application at any time. Pre-proposals will be reviewed by MJFF within three weeks of submission. Applicants whose pre-proposal is selected for further consideration will be invited to submit a full proposal through one of the four review cycles. 

This program seeks to advance therapeutic development through pre-clinical and/or clinical testing of approaches addressing unmet needs of people with Parkinson’s disease (PD). The program is set up to benefit therapeutics with clear potential to prevent, stop, or delay disease progression or to reduce the burden of daily symptoms.

The Therapeutics Pipeline Program is only open to industry and industry-academia collaborations.

Funding: Award amounts for this program may range from $250,000 for smaller, targeted programs to upwards of $2M for larger, multi-stage preclinical and/or clinical programs

Duration: 1-2 years for pre-clinical programs, 2-3 years for clinical programs

https://www.michaeljfox.org/grant/parkinsons-disease-therapeutics-pipeline-program?em_cid=mc-a1bHq00000AbgaK

Seek applications from early-career basic scientists, medical oncologists, pathologists, urologists, radiologists, radiation oncologists, public health experts, bioinformaticians, bioengineers, or professionals from any other field that could contribute to the end of potentially lethal

prostate cancer. Applicants may be working in basic, translational, computational, or clinical research in an academic or community research organization and need not be trained specifically in prostate cancer research to be highly competitive.

However, successful applicants should be working in a research environment capable of supporting transformational prostate cancer research.

Funding: $75K per year for 3 years (No overhead)

https://res.cloudinary.com/pcf/images/v1767986564/RFA_2026-Young-Investigator-Award_FINAL/RFA_2026-Young-Investigator-Award_FINAL.pdf

To provide newly independent investigators with funding that will allow them to develop preliminary or pilot data, to test procedures and to develop hypotheses. The intent is to support early-career development of newly independent researchers / clinicians that will lay the groundwork for future research grant applications to federal or other funding entities.
* For early-career investigators who have been in the position of an Assistant Professor or the equivalent for no more than seven years.
Funding: $200K for 3 years (10% overhead included)
https://www.alz.org/research/for_researchers/grants/types-of-grants/aarga

Applicants should be junior faculty members and/or postdoctoral fellows who have had a focus in clinical research on B cell or plasma cell malignancies for at least 2 years.

The Award supports talented young investigators with a background in hematology and/or oncology, encouraging them to either enter or continue WM research. A successful applicant’s academic program must have a formal teaching curriculum and mentoring from established investigators with a proven record of advancing relevant research in the B-cell malignancy or plasma cell malignancy field. Priority will be given to translational research proposals; however, applications addressing critical questions in basic discovery science relevant to WM biology and pathogenesis will be considered.  The IWMF seeks applications for research and clinical studies that will have a meaningful impact on WM patients within the next 3-5 years.

Funding: $160,000 over 2 years.

www.iwmf.com/applying-for-a-research-grant

www.iwmf.com/wp-content/uploads/2025/09/IWMF-2026-KYLE-AWARD-GRANTS-RFP_FINAL.pdf

Applications for research projects aimed at advancing the understanding and treatment of Dyspraxia or motor coordination difficulties in general.
Particularly interested in proposals that align with the following key areas:
– Advancing the Understanding of DCD.
– Reflect a core area of need highlighted in the JLA priority setting exercise for DCD / Dyspraxia.
– Motor Coordination Difficulties in Other Neurodevelopmental Conditions.
– Supporting Interventions to Enhance Motor Skills.
Funding: Funding is typically between £40K and £65K per research project. A special exception is for projects with unavoidable directly incurred high-cost materials, where we can accept projects up to £80K, with justification of costs.
https://waterloofoundation.org.uk/childdevelopmentresearchactivecallsmotorcoordination/

Aiming at supporting fundamental, translational and clinical research programs related to research on intellectual deficiencies of genetic origin solely with the exclusion of Trisomy 21.
Pilot or exploratory grants
For early stage research projects built on preliminary data or small projects that complement larger primary projects.
Funding: 50K EUR for 2 years
Advanced grants
For larger breakthrough projects with substantial preliminary data.
Funding: 80K EUR for 2 years
https://www.research.fondationlejeune.org/call-for-projets/

AFSA’s focus is to identify the biological mechanisms of FM, evaluate treatments, and look for diagnostic markers that can easily be used in a clinical setting. Proposals must be clinically focused and patient relevant.  AFSA’s priorities:

• Test therapeutic interventions or agents for reducing key FM symptoms.
• Evaluate/identify peripheral and central biological mechanisms responsible for causing FM.
• Identify/develop diagnostic measures that can be used in a clinical setting, preferably using blood or other easily accessed biofluids. This does not include brain imaging techniques because of cost and barriers with implementation.

Funding: Up to $85,000 for 1-2 years.

www.fibromyalgiafund.org/grant-guidelines

Focused on profound autism and severe, intense, and dangerous behaviors. Priority will be given to projects that identify biological mechanisms, evaluate treatments or interventions, or address barriers to conducting research with individuals who have profound autism.
Funding: up to $35K for 1 year (No Overhead)
https://autismsciencefoundation.org/apply-for-a-profound-autism-pilot-grant/
* A virtual Q&A session will be held on Monday, December 22, 2025, at 1:00 PM ET: https://us06web.zoom.us/meeting/register/fPqvJ5MCTAWQ89pMJ9_fYw#/registration

Intended to:
– Identify outstanding clinical and basic scientists in European diabetes research at a critical stage in their career.
– Support them in their transition to a tenured academic appointment in diabetes research in Europe.
– Foster their development into the leaders of tomorrow.
Applicants must be scientists and clinicians at an intermediate stage of their career, with 7-12 years of experience since completion of their most recent degree.
Funding: 5M DKK (~€670K) in 5 annual instalments of up to 1M DKK (~€134K).
https://www.europeandiabetesfoundation.org/programmes/programme-calls/efsd-and-novo-nordisk-foundation-future-leaders-award-programme/
www.europeandiabetesfoundation.org/programmes/current-funding-opportunities

* The main applicant must be associated to/employed at a university or institution in Denmark during the project period. The co-applicant(s) can be anchored in Denmark or abroad.
Aims to support synergistic research collaborations rooted in data science and computational science with immediate or potential future applications within areas of relevance to NNF’s strategy.
The project may include up to 5 collaborators. The proposed research project should demonstrate synergistic collaboration between different research groups, typically from different institutions/departments and different scientific disciplines.
Funding: The maximal size of the grant scales with the size of the collaborative consortia. Maximally DKK 14M ($2.2M) for 2 partners, DKK 20M ($3.1M)for 3 partners, DKK 28M ($4.4M)) for 4 partners, and DKK 40M ($6.3M) for 5 partners.
https://novonordiskfonden.dk/en/grant/data-science-collaborative-research-programme-2026/

The BIOGAMI program aims to stop diseases like Alzheimer’s and other brain disorders by finding and fixing problems with proteins very early—before they clump together and damage cells. The program has two technical focus areas: (1) build next-generation artificial intelligence and experimental models for intrinsically disordered proteins (IDPs) and aggregation; and (2) leverage novel tools to develop novel therapeutic modalities that interfere with or prevent IDP misfolding and aggregation while preserving critical functions, and create novel detection capabilities that respond to early-stage IDP aggregation.

Please note: The BIOGAMI program is seeking unique multi-party teaming arrangements that enable teams to perform dynamically by bringing together the diverse expertise required for the program’s varying phases and aspects. Unlike a traditional prime/subperformer arrangement where the prime performer is the leader of the team throughout the program, the multi-party teaming structure allows different members of the team to take the lead role at different stages of the program life cycle based on expertise and experience.

https://arpa-h.gov/explore-funding/programs/biogami

https://sam.gov/workspace/contract/opp/23802b14ac3d4c79bd67c6cac7e06db5/view

Award recognizes breakthroughs in basic, clinical, or translational research led by scientists aged 52 or younger.

Funding: $100K honorarium

https://fnih.org/our-programs/powering-science/montrone-seigel-prize-in-biomedical-sciences/?bbeml=tp-dnwJc27W802R9IacBWspeg.jJJnIR1yr-U6JdX5u1oBy0Q.rf6wK9oR3U0yEJePf56BdDQ.lmziu2kWQn0-lOPhLivGxOw

To encourage innovation in research that enables the detection of the deadliest cancers at earlier stages when they can be intercepted or effectively treated, the American Association for Cancer Research (AACR), the Lustgarten Foundation, and The Mark Foundation for Cancer Research announce this Request for Proposals for projects focused on accelerating the development of effective new approaches to the early detection of cancer.
Funding: $2M for 2 years
https://themarkfoundation.org/early-detection-award/

Grant on Prevention and Early Detection in Lung Cancer 

This funding mechanism is focused on identifying, characterizing, and developing approaches and techniques that will allow early detection and/or prevention of lung cancer and gaining insight into pre-neoplastic processes in the lungs. The ultimate goal is to detect lung cancer at the earliest stages and subsequently increase survival and survivorship.

Funding: max of $150K for 2 years (Non-Profit)

Research Grant on Overcoming Resistance in Lung Cancer

Focus on furthering the understanding of the development, prevention, and therapy of resistance by supporting projects that seek to identify, characterize, treat or prevent resistance to lung cancer therapies. Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across histological subtypes of lung cancer (including lung adenocarcinoma, squamous cell carcinoma and small cell lung cancer) and across the care continuum including newly designed targeted therapies and immunotherapies. These studies will enhance the momentum of improving lung cancer outcomes and have the potential to increase survivorship.

Funding: max of $150K for 2 years (Non-Profit)

Leading Edge Research Grant Program

The goal of the LCRF Leading Edge Research Grant Program is to fund innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, disparities, and social determinants of health research.

Funding: max of $150K for 2 years (Non-Profit)

https://www.lungcancerresearchfoundation.org/research/funding-opportunities-2026/

Scientific and technological research initiatives to advance patient care in the fields of orthodontics and dentistry.

Funding: up to $25K for 1 year

https://investor.aligntech.com/news-releases/news-release-details/align-technology-opens-2026-annual-research-program-advance

Applications for highly innovative currently unfunded research projects that will ultimately reduce death and suffering from prostate cancer. This includes basic, translational, clinical, and community-based research that will significantly contribute to preventing prostate cancer metastasis, morbidity or mortality. Proposals should be composed of at least 3 investigators capable of providing unique scientific expertise to the solution of this significant problem in prostate cancer research.

Funding: $1M for 2 years (No overhead)

https://res.cloudinary.com/pcf/images/v1767918150/2026-Challenge-Award-RFA_FINAL/2026-Challenge-Award-RFA_FINAL.pdf?utm_source=newsletter&utm_medium=email&utm_campaign=request-for-applications-2026-pcf-challenge-awards

Intended to fund early stage science with unique hypotheses fostering the next generation of congenital heart defects and related pediatric heart disease research, thus creating a strong foundation of preliminary evidence to make scientific advancements.

Funding: up to $100K for 1 year (No overhead)

https://savingtinyhearts.org/research/

qualified teams of investigators from academic and community institutions that will directly contribute to improved outcomes for patients with prostate cancer with lethal potential. These awards will be funded depending on the level of innovation and transformative potential in applications received. PCF seeks high-risk, currently unfunded projects from academic and community research institutions around the world. TACTICAL Awards provide $5 – $10 Million U.S.D. per award over 3–5 years. (No overhead)

https://www.pcf.org/our-work/open-rfas-rfps/

https://res.cloudinary.com/pcf/images/v1768591135/2026-TACTICAL-Award-RFA_FINAL/2026-TACTICAL-Award-RFA_FINAL.pdf?_i=AA

The areas of current focus are Exfoliation Syndrome and Exfoliation Glaucoma, Pressure Independent Mechanisms of Glaucoma, Neuroprotection, and Genetics of Glaucomas that affect people under the age of 40 years. Research may range from basic science to clinical interventions, such as genetics and genomic medicine, disease modeling, assessment of ocular perfusion, artificial intelligence, and clinical research.
Funding: $75K for 1 year.
A grantee is permitted to apply for a one-year grant renewal of up to $75K, based on research findings from the initial research.
https://glaucomafoundation.org/research-center/grant-application-and-information/

Supports dermatology research projects worldwide that improve the understanding of the underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases and their symptoms.  We also welcome applications for projects that address clinical issues among people who are at risk of developing, or have developed, a skin disease, including how it impacts their quality of life and the societal costs involved.

Funding: 2-4 million DKK for 1-3 years.

www.leo-foundation.org/en/grants-and-awards/research-grants

www.leo-foundation.org/en/wp-content/uploads/sites/2/2025/11/Research-Grants-Application-guide-2026.pdf

Focused on the social and civic participation of adults with cerebral palsy , the objective of this call for projects is to better understand the specific needs of adults with cerebral palsy , to value their skills , and to propose concrete solutions to improve their participation in all aspects of life : education, employment, health, mobility, culture, parenting, political life, etc.

Funding: €170K for 3 years

https://fondationparalysiecerebrale.org/en/appels-a-projets/

https://fondationparalysiecerebrale.org/wp-content/uploads/2026/01/PARTAGE-2026-APPEL-A-PROJET.pdf

Designed to accelerate innovative, patient-focused research in myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET).
While all proposals relevant to MPN biology, therapy, and patient-centered outcomes are welcome, MPNRF is particularly interested in projects that apply AI/ML approaches capable of yielding measurable impact within two years, and in novel translational research addressing MPL-driven disease.
Funding: up to $125K per year for 2 years (8% overhead)
https://mpnresearchfoundation.org/mpn-challenge/

* Dermal Allograft Innovation Grants:  Translational and Clinical Research proposals that accelerate innovation in allograft dermis and skin by developing new enabling technologies, novel clinical uses, advanced processing or delivery methods, and next generation product forms.  Funding: Up to $100K for a 12-month project period.

* Innovation in Allografts Translational Grants:  High‑impact translational and clinical research that advances allograft tissue science and improves patient outcomes. Proposed research must utilize allograft tissues or allograft‑derived materials and include a clear, credible pathway toward clinical translation.  Clinical areas of interest include orthopaedics, plastic and reconstructive surgery, aesthetics, surgical soft‑tissue repair, abdominal wall reconstruction, and wound care, as well as any other specialty area where allograft transplantation technologies can drive meaningful improvement.

Funding: Junior Investigator: One‑year, $75K for investigators without prior major independent funding;  Established Investigator: Three‑year, $225K  award for investigators with prior major grant support.

www.mtfbiologics.org/who-we-serve/donors-community/researchers

www.mtfbiologics.org/docs/default-source/grant-applications/2026/mtf-biologics-2026-dermal-grant-rfp.pdf

www.mtfbiologics.org/docs/default-source/grant-applications/2026/mtf-biologics-2026-innovation-grant-rfp.pdf

Research areas of interest include, but are not limited to, the following:

• Reducing and identifying off-flavors in plant-based and fermentation-derived protein ingredients through physical, biological or computational approaches across all stages of the value chain.
• Leveraging hybrid ingredients for complementary functions that balance flavor across blended formulations.
• Designing desirable flavors by understanding and optimizing flavor precursors, extraction and reaction processes, and compound formulation.
• Reducing batch-to-batch variability in flavor attributes of protein ingredients through advances in processing control, compositional analysis and predictive modeling.

Please note the research proposed should be relevant to the to the U.S. food and agriculture system.

Funding: FFAR/GFI Requests of USD$400,000 – 500,000 are available for all proposed projects. There is no maximum on the amount of matching funds that may be included in the total budget. Projects from two (2) to three (3) years in length are eligible for funding.

https://foundationfar.org/grants-funding/opportunities/enhancing-the-flavor-of-plant-based-and-fermentation-derived-proteins-rfa/

Funds activities that hold promise of identifying therapies (cures) for paralysis in humans. It has particular focus on placing projects in the research pipeline, that is, enabling scientists to develop the proof concept data necessary to apply for larger NIH grants. The development of effective therapies for chronic injury is a high priority for the organization.  Basic research will be supported if it has clear potential to accelerate progress at the applied end of the continuum and/or if it reflects innovative research or a ‘change of direction’.

Funding: $5K to $75K for 1 year (second year considered, no overhead)

https://mcpf.org/new-investigator-grant-application/

https://mcpf.org/wp-content/uploads/2025/02/MCPF-Research-Guidelines-1.doc

Applicants may submit a pre-proposal application at any time. Pre-proposals will be reviewed by MJFF within three weeks of submission. Applicants whose pre-proposal is selected for further consideration will be invited to submit a full proposal through one of the four review cycles. 

This program seeks to advance therapeutic development through pre-clinical and/or clinical testing of approaches addressing unmet needs of people with Parkinson’s disease (PD). The program is set up to benefit therapeutics with clear potential to prevent, stop, or delay disease progression or to reduce the burden of daily symptoms.

The Therapeutics Pipeline Program is only open to industry and industry-academia collaborations.

Funding: Award amounts for this program may range from $250,000 for smaller, targeted programs to upwards of $2M for larger, multi-stage preclinical and/or clinical programs

Duration: 1-2 years for pre-clinical programs, 2-3 years for clinical programs

https://www.michaeljfox.org/grant/parkinsons-disease-therapeutics-pipeline-program?em_cid=mc-a1bHq00000AbgaK

The Foundation supports clinical research in the area of precision oral medicine fostering preventive, diagnostic and therapeutic solutions. The Foundation wishes to involve active participation of patients in research.  Focus areas in 2026:

Bio-functionalisation of regenerative biomaterials

Prognostication of regenerative wound healing

Funding: Up to 125,000 Swiss francs.

www.osteology.org/en/research/funding-opportunities/applied-research-grants

www.osteology.org/media/1naguxxg/osteology_apprg_application_guidelines_2026.pdf

A semi-annual submission for Strategic Research Agreement Letters of Intent that address Breakthrough T1D’s current Research Strategy.

https://www.breakthrought1d.org/explore-research/research-strategy/

https://www.breakthrought1d.org/explore-research/funding-opportunities/

* The main applicant must be anchored and have their primary employment and research group at a university, hospital, or other non-profit research institution in Denmark. It is possible to include one international co-applicant.
To provide catalytic funding for exploratory research projects within the thematic research areas pathogenic fungi, novel antimicrobial resistance (AMR) tools, and harnessing innate immunity. Within these thematic areas, the aim is to stimulate Danish research, strengthen international collaborations, and to initiate innovative research projects with exceptional potential for future direct impact on global challenges.
Funding: up to DKK 6.5M ($1M) for up to 3 years.
https://novonordiskfonden.dk/en/grant/infectious-diseases-catalyst-grants-2025/

* The main applicant must be anchored at a Steno Diabetes Center or a Steno Partner institution. A university, hospital, municipality or other non-profit research or diabetes care institution in Denmark or abroad is also eligible as a co-applicant.
With this call, the Novo Nordisk Foundation wishes to strengthen the collaboration between the Steno Diabetes Centers and the research environments related to the Centers. The foundation will support research projects with a unifying and collaborative mission to develop knowledge, to exchange experience across the research institutions and to facilitate synergy between the research environments around the Steno Diabetes Centers.
Funding: between DKK 300K ($47K)- DKK 10M ($1.5M) for 1-5 years.
https://novonordiskfonden.dk/en/grant/steno-collaborative-grants/

This award’s objective is to fund innovative projects to support research that examines the impact of climate change and environmental pollution on lung cancer risk, diagnosis, treatment, and outcomes and identifies strategies to mitigate these effects.

Funding: max of $200K for 2 years (Non-Profit)

https://www.lungcancerresearchfoundation.org/research/funding-opportunities-2026/

Will support the development of necessary research tools, techniques, model systems, and data collection platforms to stimulate and accelerate research on rare epilepsies.

Funding: 100K for 1 year (No overhead)

https://www.cureepilepsy.org/for-researchers/grants-program/

Applicants may submit a pre-proposal application at any time. Pre-proposals will be reviewed by MJFF within three weeks of submission. Applicants whose pre-proposal is selected for further consideration will be invited to submit a full proposal through one of the four review cycles. 

This program seeks to advance therapeutic development through pre-clinical and/or clinical testing of approaches addressing unmet needs of people with Parkinson’s disease (PD). The program is set up to benefit therapeutics with clear potential to prevent, stop, or delay disease progression or to reduce the burden of daily symptoms.

The Therapeutics Pipeline Program is only open to industry and industry-academia collaborations.

Funding: Award amounts for this program may range from $250,000 for smaller, targeted programs to upwards of $2M for larger, multi-stage preclinical and/or clinical programs

Duration: 1-2 years for pre-clinical programs, 2-3 years for clinical programs

https://www.michaeljfox.org/grant/parkinsons-disease-therapeutics-pipeline-program?em_cid=mc-a1bHq00000AbgaK

In 2026, grants are available in the following areas:

• In-vitro models and assays to identify novel therapies for neuroinflammatory diseases.  To develop predictive in-vitro models aimed at identifying and optimizing novel small molecule medicines for human neuroinflammatory diseases. One grant of up to 500K EUR over 2 years.
• Artificial intelligence in cell culture media and process development. Proposals for robust, host-agnostic, and easy to parameterize models, that enable us to more quickly develop fit-for-purpose solutions for the optimization of bioprocesses for a broad base of host organisms. One grant of up to 150K EUR/year for up to 3 years.
• Innovative approaches to economical remediation of contaminated high volume materials.  Proposals dedicated to the remediation of high-volume, low-contaminated soil and water, with a specific focus on chloro-organic pollutants and particularly those contaminated with hexachlorocyclohexane (HCH).  One grant of up to 150K EUR/year for up to 2 years.
• Condensate-based high-sensitivity cell-free screening assays for the modulation of protein-protein interactions.  One grant of up to 100K EUR/year for up to 3 years.
• Advancing molecule synthesis and discovery – up to 3 grants each comprising a 1-year full Synthia® Retrosynthesis Software license, training, and extensive interaction with our scientists.

www.merckgroup.com/en/research/open-innovation/research-grants.html

These awards will help pioneer and accelerate novel drug development for the treatment of Parkinson’s, providing researchers the opportunity to generate the essential data and help bridge the gaps needed to get their projects/compounds ready to enter full scale drug discovery with an industry partner or the Parkinson’s Virtual Biotech.

Looking for projects that will have a clear focus on translational drug development to make a difference to those affected by Parkinson’s.

Funding: There is no minimum award amount and the maximum award amount is £150,000.

For projects involving in vivo work, an award amount of up to £200,000 will be considered.

Lead PI must be UK based

https://www.parkinsons.org.uk/research/drug-accelerator-awards

Aiming at supporting fundamental, translational and clinical research programs related to research on intellectual deficiencies of genetic origin
exclusively dedicated to Trisomy 21 research.
Pilot or exploratory grants
For early stage research projects built on preliminary data or small projects that complement larger primary projects.
Funding: 50K EUR for 2 years
Advanced grants
For larger breakthrough projects with substantial preliminary data.
Funding: 80K EUR for 2 years
https://www.research.fondationlejeune.org/call-for-projets/

Funds activities that hold promise of identifying therapies (cures) for paralysis in humans. It has particular focus on placing projects in the research pipeline, that is, enabling scientists to develop the proof concept data necessary to apply for larger NIH grants. The development of effective therapies for chronic injury is a high priority for the organization.  Basic research will be supported if it has clear potential to accelerate progress at the applied end of the continuum and/or if it reflects innovative research or a ‘change of direction’.

Funding: $5K to $75K for 1 year (second year considered, no overhead)

https://mcpf.org/new-investigator-grant-application/

https://mcpf.org/wp-content/uploads/2025/02/MCPF-Research-Guidelines-1.doc

We support innovative basic, translational, and clinical research that advances understanding and care for LGS.
Priority Research Areas: LGS biomarkers that predict disease course and/or treatment response / Mortality in LGS / Medical device use in LGS / Disease-modifying therapies targeted to the LGS Secondary Brain Network / Natural history of LGS / Non-seizure issues & quality of life in LGS / Prevention, reversal, and/or stabilization of LGS / Neurodegeneration in LGS / Pediatric-to-adult transition of care in LGS
Funding: up to $75K over 1–2 years.
www.lgsfoundation.org/365-research-grant
www.lgsfoundation.org/wp-content/uploads/2025/11/RFP_-LOI-and-Full-Proposal-Instructions-.docx.pdf

 (Abstracts may be submitted at any time until the closing date)

AOI #20 DRIVe Forward

Aims to develop products, capabilities, and technologies to detect threats, improve patient care, including ancillary supplies and resources, as well as novel approaches to develop, clinically validate, and deploy/distribute MCMs rapidly and agnostically.

Especially interested in proposals that aim to address one or more of the following topics:

1. Microbiome-based therapies
2. Resilience to infection
3. Next-generation vaccines
4. Next-generation therapeutic antibodies
5. Artificial blood products
6. Extremely mobile viral diagnostic platforms for use in extremely remote settings
7. Non-pharmacological approaches for enhanced immunity

Funding: up to $750K.

https://drive.hhs.gov/partner.html

https://drive.hhs.gov/files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_01.pdf

(Pre-proposals/pre-applications may be submitted at any time throughout the 5-year period from the BAA release date to the BAA closing date)

Research Areas of Interest (please see BAA for more details)

1. Damage Control Resuscitation
2. Prolonged Field Care (PFC)
3. Portable Lab Assays and Diagnostics
4. Force Health Protection and Environmental Medicine
5. Brain Health
6. Immune Response
7. Chronic Pain
8. Automation of Systematic Reviews and Metanalysis
9. Medical Simulation and Training Technologies
10. Human Performance Optimization
11. Canine Medicine and Performance

Most projects are anticipated to have a total cost at or below $1,500,000 (including indirect costs). Projects that have a total cost higher than $1,500,000 (including Indirect costs) with outstanding scientific merit that meet a critical need may be accepted; however the total cost of these projects are not to exceed $5,000,000.00 (including Indirect costs).

Duration: up to 5 years.

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=549113